TY - JOUR
T1 - Meaning and purpose in Huntington’s disease
T2 - a longitudinal study of its impact on quality of life
AU - Sokol, Leonard L.
AU - Troost, Jonathan P.
AU - Kluger, Benzi M.
AU - Applebaum, Allison J.
AU - Paulsen, Jane S.
AU - Bega, Danny
AU - Frank, Samuel
AU - Hauser, Joshua M.
AU - Boileau, Nicholas R.
AU - Depp, Colin A.
AU - Cella, David
AU - Carlozzi, Noelle E.
N1 - Funding Information:
Data reported in this manuscript were collected with support from the National Institutes of Health (NIH), National Institute of Neurological Disorders and Stroke (R01NS077946: PI Carlozzi; R01NS0400068: PI Paulsen), and the National Center for Advancing Translational Sciences (UL1TR000433). Jonathan Troost was supported in part by the National Center for Advancing Translational Sciences (NCATS) for the Michigan Institute for Clinical and Health Research (UL1TR002240).
Funding Information:
Dr Sokol is an ad‐hoc consultant for Tikvah for Parkinson in the range of $0–$499, ad‐hoc consultant for the American Film Institute on end‐of‐life care/palliative care in the enrage of $500–$999; and receives financial support from the Northwestern PSTP Program in Neurology as well as the R25 NCI 2R25CA190169. Dr Troost has research funding through the University of Michigan with Complexa Inc, Retrophin Inc, and Goldfinch Bio, and the University of Michigan with Vertex Pharmaceuticals and Pfizer Inc. Dr Kluger received research grant support from the National Institute of Aging, National Institute of Nursing Research, and Patient‐Centered Outcomes Research Institute; he has received speaker honoraria from the Parkinson’s Foundation. Dr Applebaum receives financial support from the National Cancer Institute. Dr Paulsen receives support from the NINDS and NIBIB and has received personal compensation in the range of $0–$499 for serving on a Scientific Advisory or Data Safety Monitoring Board for Wave Life Sciences, has received personal compensation in the range of $0–$499 for serving on a Speakers Bureau for HDSA, and has received personal compensation in the range of $0–$499 for serving as a consultant with Acadia. Dr Bega has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Speaker: Teva Pharmaceuticals, Acorda Therapeutics, Neurocrine Biosciences, Adamas Pharmaceuticals Consulting: Biogen Pharmaceuticals, Amgen Pharmaceuticals, Acadia Pharmaceuticals, Genentech, Inc, GE Healthcare, Gerson Lehrman Group, Guidepoint, L.E.K. C., and has received personal compensation in an editorial capacity for Editor: Annals of Clinical & Translational Neurology. Dr Frank has received personal compensation in the range of $500–$4999 for serving as a Consultant for Oscine Therapeutics. Dr Frank has received personal compensation in the range of $500–$4999 for serving as a Consultant for uniQure, has received personal compensation in the range of $500–$4999 for serving as a Consultant for MCG Health. The institution of Dr Frank has received research support from the Huntington’s Disease Society of America. The institution of Dr Frank has received research support from Michael J Fox Foundation. The institution of Dr Frank has received research support from Roche/Genentech. The institution of Dr Frank has received research support from CHDI Foundation. The institution of Dr Frank has received research support from the Huntington Study Group. The institution of Dr Frank has received research support from Triplet Therapeutics. Dr Hauser is supported or has received support from the Coleman Foundation, University of Florida, Instituto Nacional de Caˆncer, American Academy of Hospice and Palliative Medicine, Arnold P. Gold Foundation, National Institute on Aging, Seasons Hospice Foundation, Woodstock, HCSC Insurance Services Company, National Heart, Lung, and Blood Institute, Canadian Patient Safety Institute, Health Research, and Educational Trust, Icahn School of Medicine at Mount Sinai, Centers for Medicare and Medicaid Services, Agency for Healthcare Research and Quality, Children’s Hospitals and Clinics of Minnesota, Instituto Nacional de Caˆncer, Department of Veterans Affairs, National Center for Research Resources, NOVA Research Company, Instituto Nacional de Caˆncer, Lance Armstrong Foundation, Retirement Research Foundation, Society for the Arts in Healthcare, Medical College of Wisconsin, and the National Institute of Nursing Research. Dr Boileau reports no disclosures. Dr Depp receives support from the NIMH, VA, and NCATS. Dr Cella has research funding to his institution from NIH, Abbvie, Amgen, Bayer Healthcare, Bristol‐Myers Squibb, Clovis, Eli Lilly and Company, Glaxo Smith‐Kline, Johnson and Johnson, Novartis, Pfizer, and PledPharma; he has served as a consultant to Abbvie, Bristol‐Myers Squibb, Eli Lilly and Company, Johnson and Johnson, Novartis, and Pfizer. Dr Cella is the president of FACIT.org. Dr Carlozzi reports research grants from the NIH, the Neilsen Foundation, and CHDI, as well as contracts from Goldfinch, LLC, and Health and Human Services – Centers for Medicare & Medicaid Services; she receives honoraria for her role on the CHDI scientific advisory board and is a consultant on the TBI Congressionally mandated study.
Publisher Copyright:
© 2021 The Authors. Annals of Clinical and Translational Neurology published by Wiley Periodicals LLC on behalf of American Neurological Association
PY - 2021/8
Y1 - 2021/8
N2 - Objective: Previous work in Huntington’s disease (HD) has shown that a sense of meaning and purpose (M&P) is positively associated with positive affect and well-being (PAW); however, it was unknown whether HD-validated patient-reported outcomes (PROs) influence this association and how M&P impacts PROs in the future. Our study was designed to examine if HD-validated PROs moderate the relationship between M&P and PAW and to evaluate if baseline M&P predicts 12- and 24-month changes in HD-validated PROs. Methods: This was a longitudinal, multicenter study to develop several PROs (e.g., specific for the physical, emotional, cognitive, and social domains) for people with HD (HDQLIFE). The sample consisted of 322 people with HD (n = 50 prodromal, n = 171 early-stage manifest, and n = 101 late-stage manifest HD). A single, multivariate linear mixed-effects model was performed with PAW as the outcome predicted by main effects for M&P and several moderators (i.e., an HD-validated PRO) and interactions between M&P and a given PRO. Linear-mixed models were also used to assess if baseline M&P predicted HD-validated PROs at 12 and 24 months. Results: Higher M&P was positively associated with higher PAW regardless of the magnitude of symptom burden, as represented by HD-validated PROs, and independent of disease stage. In our primary analysis, baseline M&P predicted increased PAW and decreased depression, anxiety, anger, emotional/behavioral disruptions, and cognitive decline at 12 and 24 months across all disease stages. Interpretation: These findings parallel those seen in the oncology population and have implications for adapting and developing psychotherapeutic and palliative HD interventions.
AB - Objective: Previous work in Huntington’s disease (HD) has shown that a sense of meaning and purpose (M&P) is positively associated with positive affect and well-being (PAW); however, it was unknown whether HD-validated patient-reported outcomes (PROs) influence this association and how M&P impacts PROs in the future. Our study was designed to examine if HD-validated PROs moderate the relationship between M&P and PAW and to evaluate if baseline M&P predicts 12- and 24-month changes in HD-validated PROs. Methods: This was a longitudinal, multicenter study to develop several PROs (e.g., specific for the physical, emotional, cognitive, and social domains) for people with HD (HDQLIFE). The sample consisted of 322 people with HD (n = 50 prodromal, n = 171 early-stage manifest, and n = 101 late-stage manifest HD). A single, multivariate linear mixed-effects model was performed with PAW as the outcome predicted by main effects for M&P and several moderators (i.e., an HD-validated PRO) and interactions between M&P and a given PRO. Linear-mixed models were also used to assess if baseline M&P predicted HD-validated PROs at 12 and 24 months. Results: Higher M&P was positively associated with higher PAW regardless of the magnitude of symptom burden, as represented by HD-validated PROs, and independent of disease stage. In our primary analysis, baseline M&P predicted increased PAW and decreased depression, anxiety, anger, emotional/behavioral disruptions, and cognitive decline at 12 and 24 months across all disease stages. Interpretation: These findings parallel those seen in the oncology population and have implications for adapting and developing psychotherapeutic and palliative HD interventions.
UR - http://www.scopus.com/inward/record.url?scp=85110627247&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85110627247&partnerID=8YFLogxK
U2 - 10.1002/acn3.51424
DO - 10.1002/acn3.51424
M3 - Article
C2 - 34288600
AN - SCOPUS:85110627247
SN - 2328-9503
VL - 8
SP - 1668
EP - 1679
JO - Annals of Clinical and Translational Neurology
JF - Annals of Clinical and Translational Neurology
IS - 8
ER -